Truist Financial Corp Sells 169 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Truist Financial Corp lowered its stake in ICU Medical, Inc. (NASDAQ:ICUIGet Rating) by 4.7% in the first quarter, HoldingsChannel.com reports. The firm owned 3,394 shares of the medical instruments supplier’s stock after selling 169 shares during the quarter. Truist Financial Corp’s holdings in ICU Medical were worth $756,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ICUI. Advisor Group Holdings Inc. increased its holdings in shares of ICU Medical by 7.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 847 shares of the medical instruments supplier’s stock valued at $202,000 after purchasing an additional 59 shares in the last quarter. Inspire Investing LLC acquired a new stake in shares of ICU Medical in the first quarter valued at approximately $233,000. Equitable Trust Co. increased its holdings in shares of ICU Medical by 3.7% in the fourth quarter. Equitable Trust Co. now owns 1,307 shares of the medical instruments supplier’s stock valued at $310,000 after purchasing an additional 47 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of ICU Medical in the fourth quarter valued at approximately $311,000. Finally, Janney Montgomery Scott LLC increased its holdings in shares of ICU Medical by 36.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 1,472 shares of the medical instruments supplier’s stock valued at $349,000 after purchasing an additional 395 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ICUI. TheStreet lowered shares of ICU Medical from a “b-” rating to a “c” rating in a report on Wednesday, May 11th. StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Thursday, May 12th.

Insider Transactions at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 750 shares of ICU Medical stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $173.56, for a total transaction of $130,170.00. Following the transaction, the vice president now directly owns 3,371 shares of the company’s stock, valued at $585,070.76. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Elisha W. Finney sold 217 shares of the business’s stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $170.53, for a total value of $37,005.01. Following the sale, the director now directly owns 1,933 shares of the company’s stock, valued at approximately $329,634.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 750 shares of the business’s stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $173.56, for a total transaction of $130,170.00. Following the completion of the sale, the vice president now directly owns 3,371 shares in the company, valued at $585,070.76. The disclosure for this sale can be found here. Insiders own 7.30% of the company’s stock.

ICU Medical Price Performance

ICUI opened at $172.72 on Monday. The company has a fifty day moving average price of $171.58 and a two-hundred day moving average price of $202.96. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.29 and a current ratio of 2.38. ICU Medical, Inc. has a 52 week low of $158.60 and a 52 week high of $282.00. The firm has a market capitalization of $4.13 billion, a PE ratio of 84.67 and a beta of 0.53.

ICU Medical (NASDAQ:ICUIGet Rating) last announced its quarterly earnings results on Monday, May 9th. The medical instruments supplier reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.53 by ($0.21). The firm had revenue of $543.10 million for the quarter, compared to the consensus estimate of $557.33 million. ICU Medical had a return on equity of 7.89% and a net margin of 2.68%. The company’s revenue for the quarter was up 70.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 earnings per share. As a group, analysts anticipate that ICU Medical, Inc. will post 7.68 earnings per share for the current year.

About ICU Medical

(Get Rating)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs.

Recommended Stories

Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUIGet Rating).

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.